Chemicals
Showing 11851–12000 of 41137 results
-
Smoothened (Smo) is a cell surface receptor that, with Patched, mediates sonic hedgehog (Shh) signaling to regulate gene expression through the Gli transcription factors.{21774} BMS 833923 is an orally bioavailable inhibitor of Smo.{27708,27709} It blocks binding of BODIPY cyclopamine (IC50 = 21 nM) and inhibits Gli activation in cell lines that express wild-type Smo or activated mutant forms of Smo (IC50s = 6-35 nM). BMS 833923 robustly inhibits Shh pathway activity and prevents tumor growth in medulloblastoma and pancreatic carcinoma xenograft models.
Brand:CaymanSKU:-
BMS 986020 is a potent G protein-coupled lysophosphatidic acid receptor 1 (LPA1) antagonist with an IC50 value less than 300 nM for human LPA1 expressing CHO cells.{37079} Formulations containing BMS 986020 are being investigated in clinical trials for efficacy in idiopathic pulmonary fibrosis.{37080}
Brand:CaymanSKU:22049 -Out of stock
BMS 986020 is a potent G protein-coupled lysophosphatidic acid receptor 1 (LPA1) antagonist with an IC50 value less than 300 nM for human LPA1 expressing CHO cells.{37079} Formulations containing BMS 986020 are being investigated in clinical trials for efficacy in idiopathic pulmonary fibrosis.{37080}
Brand:CaymanSKU:22049 -Out of stock
BMS 986120 is an orally bioavailable, selective, and reversible antagonist of proteinase-activated receptor 4 (PAR4; IC50 = 0.56 nM to inhibit calcium mobilization induced by PAR4 agonist peptide (PAR4-AP) in HEK293 cells).{36234} It is selective for PAR4 over PAR1, PAR2, and a panel of purified proteases, including thrombin. It inhibits platelet aggregation in vitro in human platelet-rich plasma (IC50 = 7.3 nM). BMS 986120 (0.2-1 mg/kg) decreases platelet aggregation induced by PAR4-AP ex vivo in a dose-dependent manner, but does not increase clotting times. In vivo, BMS 986120 (1 mg/kg) prevents vascular occlusion and reduces thrombus formation by 82% in cynomolgus monkeys.
Brand:CaymanSKU:23497 - 1 mgAvailable on backorder
BMS 986120 is an orally bioavailable, selective, and reversible antagonist of proteinase-activated receptor 4 (PAR4; IC50 = 0.56 nM to inhibit calcium mobilization induced by PAR4 agonist peptide (PAR4-AP) in HEK293 cells).{36234} It is selective for PAR4 over PAR1, PAR2, and a panel of purified proteases, including thrombin. It inhibits platelet aggregation in vitro in human platelet-rich plasma (IC50 = 7.3 nM). BMS 986120 (0.2-1 mg/kg) decreases platelet aggregation induced by PAR4-AP ex vivo in a dose-dependent manner, but does not increase clotting times. In vivo, BMS 986120 (1 mg/kg) prevents vascular occlusion and reduces thrombus formation by 82% in cynomolgus monkeys.
Brand:CaymanSKU:23497 - 10 mgAvailable on backorder
BMS 986120 is an orally bioavailable, selective, and reversible antagonist of proteinase-activated receptor 4 (PAR4; IC50 = 0.56 nM to inhibit calcium mobilization induced by PAR4 agonist peptide (PAR4-AP) in HEK293 cells).{36234} It is selective for PAR4 over PAR1, PAR2, and a panel of purified proteases, including thrombin. It inhibits platelet aggregation in vitro in human platelet-rich plasma (IC50 = 7.3 nM). BMS 986120 (0.2-1 mg/kg) decreases platelet aggregation induced by PAR4-AP ex vivo in a dose-dependent manner, but does not increase clotting times. In vivo, BMS 986120 (1 mg/kg) prevents vascular occlusion and reduces thrombus formation by 82% in cynomolgus monkeys.
Brand:CaymanSKU:23497 - 5 mgAvailable on backorder
![A positive allosteric modulator of μ-opioid receptors (EC50 = 3 μM for endomorphin 1-stimulated β-arrestin recruitment in U2OS-OPRM1 cells expressing human μ-opioid receptors); potentiates endomorphin 1-induced inhibition of forskolin-stimulated adenylyl cyclase activity in CHO cells expressing human μ-opioid receptors (EC50 = 8.9 μM); enhances DAMGO-stimulated [35S]GTPγ binding in C6μ glioma cell membranes and mouse brain membranes](https://interpriseusa.com/wp-content/uploads/2021/06/23269.png)
BMS 986122 is a positive allosteric modulator of μ-opioid receptors that increases β-arrestin recruitment stimulated by endomorphin 1 (Item No. 23280) in U2OS-OPRM1 human osteosarcoma cells expressing μ-opioid receptors (EC50 = 3 μM).{37687} It potentiates endomorphin 1-induced inhibition of forskolin-stimulated adenylyl cyclase activity in CHO cells expressing human recombinant μ-opioid receptors (EC50 = 8.9 μM). BMS 986122 also enhances [35S]GTPγ binding stimulated by the μ-opioid agonist DAMGO (Item No. 21553) by 7- and 4.5-fold in C6μ glioma cell membranes that express μ-opioid receptors and mouse brain membranes, respectively.
Brand:CaymanSKU:23269 - 1 mgAvailable on backorder
BMS 986122 is a positive allosteric modulator of μ-opioid receptors that increases β-arrestin recruitment stimulated by endomorphin 1 (Item No. 23280) in U2OS-OPRM1 human osteosarcoma cells expressing μ-opioid receptors (EC50 = 3 μM).{37687} It potentiates endomorphin 1-induced inhibition of forskolin-stimulated adenylyl cyclase activity in CHO cells expressing human recombinant μ-opioid receptors (EC50 = 8.9 μM). BMS 986122 also enhances [35S]GTPγ binding stimulated by the μ-opioid agonist DAMGO (Item No. 21553) by 7- and 4.5-fold in C6μ glioma cell membranes that express μ-opioid receptors and mouse brain membranes, respectively.
Brand:CaymanSKU:23269 - 5 mgAvailable on backorder
BMS 986142 is a Bruton’s tyrosine kinase (BTK) inhibitor (IC50 = 0.5 nM).{61007} It is greater than 20-fold selective for BTK over a panel of 384 kinases. BMS 986142 inhibits calcium flux in Ramos B cells induced by B cell receptor (BCR) stimulation (IC50 = 9 nM), as well as BCR stimulation-induced proliferation of, and CD86 surface expression in, peripheral B cells (IC50s = 3 and 4 nM, respectively). It inhibits TNF-α production in human peripheral blood mononuclear cells (PBMCs) induced by Fcγ receptor stimulation (IC50 = 3 nM). BMS 986142 (30 mg/kg per day) reduces the percentage of mice with severe proteinuria and increases survival in an NZB/W lupus-prone mouse model. It reduces hind paw tibiotarsal joint bone resorption and inflammation in a mouse model of collagen antibody-induced arthritis (CAIA) when administered at doses of 5 and 20 mg/kg.{61000}
Brand:CaymanSKU:30927 - 1 mgAvailable on backorder
BMS 986142 is a Bruton’s tyrosine kinase (BTK) inhibitor (IC50 = 0.5 nM).{61007} It is greater than 20-fold selective for BTK over a panel of 384 kinases. BMS 986142 inhibits calcium flux in Ramos B cells induced by B cell receptor (BCR) stimulation (IC50 = 9 nM), as well as BCR stimulation-induced proliferation of, and CD86 surface expression in, peripheral B cells (IC50s = 3 and 4 nM, respectively). It inhibits TNF-α production in human peripheral blood mononuclear cells (PBMCs) induced by Fcγ receptor stimulation (IC50 = 3 nM). BMS 986142 (30 mg/kg per day) reduces the percentage of mice with severe proteinuria and increases survival in an NZB/W lupus-prone mouse model. It reduces hind paw tibiotarsal joint bone resorption and inflammation in a mouse model of collagen antibody-induced arthritis (CAIA) when administered at doses of 5 and 20 mg/kg.{61000}
Brand:CaymanSKU:30927 - 5 mgAvailable on backorder
BMS 986142 is a Bruton’s tyrosine kinase (BTK) inhibitor (IC50 = 0.5 nM).{61007} It is greater than 20-fold selective for BTK over a panel of 384 kinases. BMS 986142 inhibits calcium flux in Ramos B cells induced by B cell receptor (BCR) stimulation (IC50 = 9 nM), as well as BCR stimulation-induced proliferation of, and CD86 surface expression in, peripheral B cells (IC50s = 3 and 4 nM, respectively). It inhibits TNF-α production in human peripheral blood mononuclear cells (PBMCs) induced by Fcγ receptor stimulation (IC50 = 3 nM). BMS 986142 (30 mg/kg per day) reduces the percentage of mice with severe proteinuria and increases survival in an NZB/W lupus-prone mouse model. It reduces hind paw tibiotarsal joint bone resorption and inflammation in a mouse model of collagen antibody-induced arthritis (CAIA) when administered at doses of 5 and 20 mg/kg.{61000}
Brand:CaymanSKU:30927 - 500 µgAvailable on backorder
BMS 986158 is a BET bromodomain inhibitor with anticancer activity.{46357} It decreases c-Myc expression and induces cancer cell death in c-Myc-driven cancer cell lines in vitro. BMS 986158 inhibits tumor growth in triple-negative breast, colorectal, and lung cancer patient-derived mouse xenograft models.
Brand:CaymanSKU:27789 - 1 mgAvailable on backorder
BMS 986158 is a BET bromodomain inhibitor with anticancer activity.{46357} It decreases c-Myc expression and induces cancer cell death in c-Myc-driven cancer cell lines in vitro. BMS 986158 inhibits tumor growth in triple-negative breast, colorectal, and lung cancer patient-derived mouse xenograft models.
Brand:CaymanSKU:27789 - 10 mgAvailable on backorder
BMS 986158 is a BET bromodomain inhibitor with anticancer activity.{46357} It decreases c-Myc expression and induces cancer cell death in c-Myc-driven cancer cell lines in vitro. BMS 986158 inhibits tumor growth in triple-negative breast, colorectal, and lung cancer patient-derived mouse xenograft models.
Brand:CaymanSKU:27789 - 25 mgAvailable on backorder
BMS 986158 is a BET bromodomain inhibitor with anticancer activity.{46357} It decreases c-Myc expression and induces cancer cell death in c-Myc-driven cancer cell lines in vitro. BMS 986158 inhibits tumor growth in triple-negative breast, colorectal, and lung cancer patient-derived mouse xenograft models.
Brand:CaymanSKU:27789 - 5 mgAvailable on backorder
BMS 986187 is a positive allosteric modulator of δ-opioid receptors.{38565} In the presence of the endogenous δ-opioid receptor agonist leu-enkephalin, BMS 986187 has an average EC50 value of 30 nM for β-arrestin recruitment, but has little to no activity in the absence of an agonist. It is 100-fold selective for δ- over µ-opioid receptors in the presence of leu-enkephalin and the endogenous µ-opioid receptor agonist endomorphin I, respectively.
Brand:CaymanSKU:21549 -Out of stock
BMS 986187 is a positive allosteric modulator of δ-opioid receptors.{38565} In the presence of the endogenous δ-opioid receptor agonist leu-enkephalin, BMS 986187 has an average EC50 value of 30 nM for β-arrestin recruitment, but has little to no activity in the absence of an agonist. It is 100-fold selective for δ- over µ-opioid receptors in the presence of leu-enkephalin and the endogenous µ-opioid receptor agonist endomorphin I, respectively.
Brand:CaymanSKU:21549 -Out of stock
BMS 986187 is a positive allosteric modulator of δ-opioid receptors.{38565} In the presence of the endogenous δ-opioid receptor agonist leu-enkephalin, BMS 986187 has an average EC50 value of 30 nM for β-arrestin recruitment, but has little to no activity in the absence of an agonist. It is 100-fold selective for δ- over µ-opioid receptors in the presence of leu-enkephalin and the endogenous µ-opioid receptor agonist endomorphin I, respectively.
Brand:CaymanSKU:21549 -Out of stock
BMS 986188 is a positive allosteric modulator of δ-opioid receptors, with an EC50 value of 0.05 μM in a β-arrestin recruitment assay in the presence, but not absence, of the opioid receptor agonist leu-enkephalin (Item No. 23283).{38565} It is selective for δ- over μ-opioid receptors (EC50 = >10 μM) in the presence of leu-enkephalin and the μ-opioid receptor agonist endomorphin 1 (Item No. 23280), respectively.
Brand:CaymanSKU:21548 -Out of stock
BMS 986188 is a positive allosteric modulator of δ-opioid receptors, with an EC50 value of 0.05 μM in a β-arrestin recruitment assay in the presence, but not absence, of the opioid receptor agonist leu-enkephalin (Item No. 23283).{38565} It is selective for δ- over μ-opioid receptors (EC50 = >10 μM) in the presence of leu-enkephalin and the μ-opioid receptor agonist endomorphin 1 (Item No. 23280), respectively.
Brand:CaymanSKU:21548 -Out of stock
BMS 986188 is a positive allosteric modulator of δ-opioid receptors, with an EC50 value of 0.05 μM in a β-arrestin recruitment assay in the presence, but not absence, of the opioid receptor agonist leu-enkephalin (Item No. 23283).{38565} It is selective for δ- over μ-opioid receptors (EC50 = >10 μM) in the presence of leu-enkephalin and the μ-opioid receptor agonist endomorphin 1 (Item No. 23280), respectively.
Brand:CaymanSKU:21548 -Out of stock
BMS 986205 is an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IC50 = 50s = 1.1 and 1.7 nM, respectively).
Brand:CaymanSKU:25025 - 1 mgAvailable on backorder
BMS 986205 is an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IC50 = 50s = 1.1 and 1.7 nM, respectively).
Brand:CaymanSKU:25025 - 10 mgAvailable on backorder
BMS 986205 is an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IC50 = 50s = 1.1 and 1.7 nM, respectively).
Brand:CaymanSKU:25025 - 25 mgAvailable on backorder
BMS 986205 is an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IC50 = 50s = 1.1 and 1.7 nM, respectively).
Brand:CaymanSKU:25025 - 5 mgAvailable on backorder
BMS-1001 is a small molecule inhibitor of the interaction between programmed death protein 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) with an IC50 value of 2.25 nM in a homogeneous time-resolved fluorescence (HTRF) binding assay.{40457}
Brand:CaymanSKU:27891 - 1 mgAvailable on backorder
BMS-1001 is a small molecule inhibitor of the interaction between programmed death protein 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) with an IC50 value of 2.25 nM in a homogeneous time-resolved fluorescence (HTRF) binding assay.{40457}
Brand:CaymanSKU:27891 - 10 mgAvailable on backorder
BMS-1001 is a small molecule inhibitor of the interaction between programmed death protein 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) with an IC50 value of 2.25 nM in a homogeneous time-resolved fluorescence (HTRF) binding assay.{40457}
Brand:CaymanSKU:27891 - 5 mgAvailable on backorder
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy.{21810} BMS-265246 is a cell-permeable inhibitor of Cdk1/cyclin B and Cdk2/cyclin E (IC50s = 6 and 9 nM, respectively).{30908} It less potently inhibits Cdk4/cyclin D (IC50 = 0.23 μM).{30908} BMS-265246 blocks the cycling of HCT116 cells (EC50 = 0.29-0.49 µM), resulting in cell cycle arrest in G2 phase.{30909}
Brand:CaymanSKU:-Available on backorder
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy.{21810} BMS-265246 is a cell-permeable inhibitor of Cdk1/cyclin B and Cdk2/cyclin E (IC50s = 6 and 9 nM, respectively).{30908} It less potently inhibits Cdk4/cyclin D (IC50 = 0.23 μM).{30908} BMS-265246 blocks the cycling of HCT116 cells (EC50 = 0.29-0.49 µM), resulting in cell cycle arrest in G2 phase.{30909}
Brand:CaymanSKU:-Available on backorder
BMS-3 is a potent inhibitor of activated LIM domain kinases LIMK1 and LIMK2 (IC50s = 5 and 6 nM, respectively).{32445} It is used to study the role of activated LIMK isoforms in the signaling of Rho family GTPases to cytoskeletal proteins, including cofilin and tubulin.{32443,32444,32446}
Brand:CaymanSKU:-Available on backorder
BMS-3 is a potent inhibitor of activated LIM domain kinases LIMK1 and LIMK2 (IC50s = 5 and 6 nM, respectively).{32445} It is used to study the role of activated LIMK isoforms in the signaling of Rho family GTPases to cytoskeletal proteins, including cofilin and tubulin.{32443,32444,32446}
Brand:CaymanSKU:-Available on backorder
BMS-3 is a potent inhibitor of activated LIM domain kinases LIMK1 and LIMK2 (IC50s = 5 and 6 nM, respectively).{32445} It is used to study the role of activated LIMK isoforms in the signaling of Rho family GTPases to cytoskeletal proteins, including cofilin and tubulin.{32443,32444,32446}
Brand:CaymanSKU:-Available on backorder
BMS-3 is a potent inhibitor of activated LIM domain kinases LIMK1 and LIMK2 (IC50s = 5 and 6 nM, respectively).{32445} It is used to study the role of activated LIMK isoforms in the signaling of Rho family GTPases to cytoskeletal proteins, including cofilin and tubulin.{32443,32444,32446}
Brand:CaymanSKU:-Available on backorder
BMS-5 is a potent inhibitor of activated LIM domain kinases LIMK1 and LIMK2 with IC50 values of 7 and 8 nM, respectively.{32445} LIMK1 and LIMK2 participate in signal pathways affecting actin dynamics by deactivating cofilin.{32443,32444} This compound can be used to study the role of activated LIMK isoforms in the signaling of Rho family GTPases to cytoskeletal proteins, including cofilin.
Brand:CaymanSKU:21072 -Out of stock
BMS-5 is a potent inhibitor of activated LIM domain kinases LIMK1 and LIMK2 with IC50 values of 7 and 8 nM, respectively.{32445} LIMK1 and LIMK2 participate in signal pathways affecting actin dynamics by deactivating cofilin.{32443,32444} This compound can be used to study the role of activated LIMK isoforms in the signaling of Rho family GTPases to cytoskeletal proteins, including cofilin.
Brand:CaymanSKU:21072 -Out of stock
BMS-5 is a potent inhibitor of activated LIM domain kinases LIMK1 and LIMK2 with IC50 values of 7 and 8 nM, respectively.{32445} LIMK1 and LIMK2 participate in signal pathways affecting actin dynamics by deactivating cofilin.{32443,32444} This compound can be used to study the role of activated LIMK isoforms in the signaling of Rho family GTPases to cytoskeletal proteins, including cofilin.
Brand:CaymanSKU:21072 -Out of stock
BMS-536924 is a dual inhibitor of insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IC50s = 100 and 73 nM, respectively).{29658} In this way, it blocks IGF-1R autophosphorylation and signaling through MEK1/2 and Akt, leading to G1 arrest and apoptosis in myeloblastic leukemia ML-1 cells. BMS-536924 reverses epithelial-to-mesenchymal transition in immortalized mammary epithelial MCF10A cells overexpressing constitutively activated IGF-1R and causes growth inhibition and polarization of breast cancer MCF-7 cells.{29655,29657} It also induces expression of cytochrome P450 3A4 isoform in primary hepatocytes.{29656}
Brand:CaymanSKU:- BMS-536924 is a dual inhibitor of insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IC50s = 100 and 73 nM, respectively).{29658} In this way, it blocks IGF-1R autophosphorylation and signaling through MEK1/2 and Akt, leading to G1 arrest and apoptosis in myeloblastic leukemia ML-1 cells. BMS-536924 reverses epithelial-to-mesenchymal transition in immortalized mammary epithelial MCF10A cells overexpressing constitutively activated IGF-1R and causes growth inhibition and polarization of breast cancer MCF-7 cells.{29655,29657} It also induces expression of cytochrome P450 3A4 isoform in primary hepatocytes.{29656}
Brand:CaymanSKU:- BMS-536924 is a dual inhibitor of insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IC50s = 100 and 73 nM, respectively).{29658} In this way, it blocks IGF-1R autophosphorylation and signaling through MEK1/2 and Akt, leading to G1 arrest and apoptosis in myeloblastic leukemia ML-1 cells. BMS-536924 reverses epithelial-to-mesenchymal transition in immortalized mammary epithelial MCF10A cells overexpressing constitutively activated IGF-1R and causes growth inhibition and polarization of breast cancer MCF-7 cells.{29655,29657} It also induces expression of cytochrome P450 3A4 isoform in primary hepatocytes.{29656}
Brand:CaymanSKU:- BMS-536924 is a dual inhibitor of insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IC50s = 100 and 73 nM, respectively).{29658} In this way, it blocks IGF-1R autophosphorylation and signaling through MEK1/2 and Akt, leading to G1 arrest and apoptosis in myeloblastic leukemia ML-1 cells. BMS-536924 reverses epithelial-to-mesenchymal transition in immortalized mammary epithelial MCF10A cells overexpressing constitutively activated IGF-1R and causes growth inhibition and polarization of breast cancer MCF-7 cells.{29655,29657} It also induces expression of cytochrome P450 3A4 isoform in primary hepatocytes.{29656}
Brand:CaymanSKU:-
BMS-777607 is an inhibitor of the Met kinase family. It inhibits Ron, Met, Tyro-3, and AxI with IC50 values of 1.8, 3.9, 4.3, and 1.1 nM, respectively.{29883} At higher concentrations it is reported to inhibit Mer, FLT3, Aurora B, Lck, and VEGFR2 (IC50s = 14, 16, 78, 120, and 180 nM, respectively).{29883} In cancer cells, BMS-777607 induces polyploidy with multiple sets of chromosomes, as well as suppresses metastasis.{29883,29882} In tumor xenograft models, BMS-777607 at 50 mg/kg/mouse inhibits the growth of tumor cells expressing Met/Ron.{29883}
Brand:CaymanSKU:-Available on backorder
BMS-777607 is an inhibitor of the Met kinase family. It inhibits Ron, Met, Tyro-3, and AxI with IC50 values of 1.8, 3.9, 4.3, and 1.1 nM, respectively.{29883} At higher concentrations it is reported to inhibit Mer, FLT3, Aurora B, Lck, and VEGFR2 (IC50s = 14, 16, 78, 120, and 180 nM, respectively).{29883} In cancer cells, BMS-777607 induces polyploidy with multiple sets of chromosomes, as well as suppresses metastasis.{29883,29882} In tumor xenograft models, BMS-777607 at 50 mg/kg/mouse inhibits the growth of tumor cells expressing Met/Ron.{29883}
Brand:CaymanSKU:-Available on backorder
BMS-777607 is an inhibitor of the Met kinase family. It inhibits Ron, Met, Tyro-3, and AxI with IC50 values of 1.8, 3.9, 4.3, and 1.1 nM, respectively.{29883} At higher concentrations it is reported to inhibit Mer, FLT3, Aurora B, Lck, and VEGFR2 (IC50s = 14, 16, 78, 120, and 180 nM, respectively).{29883} In cancer cells, BMS-777607 induces polyploidy with multiple sets of chromosomes, as well as suppresses metastasis.{29883,29882} In tumor xenograft models, BMS-777607 at 50 mg/kg/mouse inhibits the growth of tumor cells expressing Met/Ron.{29883}
Brand:CaymanSKU:-Available on backorder
BMS-777607 is an inhibitor of the Met kinase family. It inhibits Ron, Met, Tyro-3, and AxI with IC50 values of 1.8, 3.9, 4.3, and 1.1 nM, respectively.{29883} At higher concentrations it is reported to inhibit Mer, FLT3, Aurora B, Lck, and VEGFR2 (IC50s = 14, 16, 78, 120, and 180 nM, respectively).{29883} In cancer cells, BMS-777607 induces polyploidy with multiple sets of chromosomes, as well as suppresses metastasis.{29883,29882} In tumor xenograft models, BMS-777607 at 50 mg/kg/mouse inhibits the growth of tumor cells expressing Met/Ron.{29883}
Brand:CaymanSKU:-Available on backorder
BMS-8 is a small molecule inhibitor of the interaction between programmed death protein 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) with an IC50 value of 146 nM in a homogeneous time-resolved fluorescence (HTRF) binding assay.{40457}
Brand:CaymanSKU:22355 -Out of stock
BMS-8 is a small molecule inhibitor of the interaction between programmed death protein 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) with an IC50 value of 146 nM in a homogeneous time-resolved fluorescence (HTRF) binding assay.{40457}
Brand:CaymanSKU:22355 -Out of stock
BMS-8 is a small molecule inhibitor of the interaction between programmed death protein 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) with an IC50 value of 146 nM in a homogeneous time-resolved fluorescence (HTRF) binding assay.{40457}
Brand:CaymanSKU:22355 -Out of stock
BMS-8 is a small molecule inhibitor of the interaction between programmed death protein 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) with an IC50 value of 146 nM in a homogeneous time-resolved fluorescence (HTRF) binding assay.{40457}
Brand:CaymanSKU:22355 -Out of stock
BMS-806 is a small molecule that inhibits the first step of HIV-1 infection by blocking the binding of host cell CD4 with viral gp120 protein.{29893} It binds the exterior envelope glycoprotein gp120 (Kd= 21.1 nM; Ki = 24.9 nM), blocking the conformational change that occurs with CD4 binding and preventing fusion of the viral and target cell membranes.{29893,29895,29896} BMS-806 is specific to HIV-1 irrespective of chemokine receptor preference, with no activity against HIV-2, SIV, or a panel of additional viruses.{29894}
Brand:CaymanSKU:-Available on backorder
BMS-806 is a small molecule that inhibits the first step of HIV-1 infection by blocking the binding of host cell CD4 with viral gp120 protein.{29893} It binds the exterior envelope glycoprotein gp120 (Kd= 21.1 nM; Ki = 24.9 nM), blocking the conformational change that occurs with CD4 binding and preventing fusion of the viral and target cell membranes.{29893,29895,29896} BMS-806 is specific to HIV-1 irrespective of chemokine receptor preference, with no activity against HIV-2, SIV, or a panel of additional viruses.{29894}
Brand:CaymanSKU:-Available on backorder
BMS-806 is a small molecule that inhibits the first step of HIV-1 infection by blocking the binding of host cell CD4 with viral gp120 protein.{29893} It binds the exterior envelope glycoprotein gp120 (Kd= 21.1 nM; Ki = 24.9 nM), blocking the conformational change that occurs with CD4 binding and preventing fusion of the viral and target cell membranes.{29893,29895,29896} BMS-806 is specific to HIV-1 irrespective of chemokine receptor preference, with no activity against HIV-2, SIV, or a panel of additional viruses.{29894}
Brand:CaymanSKU:-Available on backorder
BMS-911543 is a potent, selective ATP-competitive inhibitor of Janus kinase 2 (JAK2) that exhibits IC50 values of 1, 356, 73, and 66 nM for JAK2, JAK1, JAK3, and TYK2, respectively.{33764} It exhibits antiproliferative activity in a variety of cell lines engineered to express the JAK2V617F activating mutation (IC50s = 60-70 nM).{33764,33765} BMS-911543 exhibited limited activity in a mouse model of JAK2V617F-driven myeloproliferative neoplasm.{33766}
Brand:CaymanSKU:21088 -Out of stock
BMS-911543 is a potent, selective ATP-competitive inhibitor of Janus kinase 2 (JAK2) that exhibits IC50 values of 1, 356, 73, and 66 nM for JAK2, JAK1, JAK3, and TYK2, respectively.{33764} It exhibits antiproliferative activity in a variety of cell lines engineered to express the JAK2V617F activating mutation (IC50s = 60-70 nM).{33764,33765} BMS-911543 exhibited limited activity in a mouse model of JAK2V617F-driven myeloproliferative neoplasm.{33766}
Brand:CaymanSKU:21088 -Out of stock
BMS-911543 is a potent, selective ATP-competitive inhibitor of Janus kinase 2 (JAK2) that exhibits IC50 values of 1, 356, 73, and 66 nM for JAK2, JAK1, JAK3, and TYK2, respectively.{33764} It exhibits antiproliferative activity in a variety of cell lines engineered to express the JAK2V617F activating mutation (IC50s = 60-70 nM).{33764,33765} BMS-911543 exhibited limited activity in a mouse model of JAK2V617F-driven myeloproliferative neoplasm.{33766}
Brand:CaymanSKU:21088 -Out of stock
BMS-911543 is a potent, selective ATP-competitive inhibitor of Janus kinase 2 (JAK2) that exhibits IC50 values of 1, 356, 73, and 66 nM for JAK2, JAK1, JAK3, and TYK2, respectively.{33764} It exhibits antiproliferative activity in a variety of cell lines engineered to express the JAK2V617F activating mutation (IC50s = 60-70 nM).{33764,33765} BMS-911543 exhibited limited activity in a mouse model of JAK2V617F-driven myeloproliferative neoplasm.{33766}
Brand:CaymanSKU:21088 -Out of stock
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX; IC50 = 8 nM) that targets Cys496 in the BMX ATP binding domain.{31496} It additionally targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent for inhibition of Blk, JAK3, EGFR, Itk, or Tec activity. BMX-IN-1 was shown to inhibit the proliferation of Tel-BMX-transformed Ba/F3 prostate cancer cells with a GI50 value of 25 nM.{31496} Antiproliferative activity was also observed in RV-1, DU-145, PC-3, and VCAP prostate cancer cell lines (GI50s = 2.54, 4.38, 5.37, and 2.46 µM, respectively).{31496}
Brand:CaymanSKU:-Available on backorder
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX; IC50 = 8 nM) that targets Cys496 in the BMX ATP binding domain.{31496} It additionally targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent for inhibition of Blk, JAK3, EGFR, Itk, or Tec activity. BMX-IN-1 was shown to inhibit the proliferation of Tel-BMX-transformed Ba/F3 prostate cancer cells with a GI50 value of 25 nM.{31496} Antiproliferative activity was also observed in RV-1, DU-145, PC-3, and VCAP prostate cancer cell lines (GI50s = 2.54, 4.38, 5.37, and 2.46 µM, respectively).{31496}
Brand:CaymanSKU:-Available on backorder
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX; IC50 = 8 nM) that targets Cys496 in the BMX ATP binding domain.{31496} It additionally targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent for inhibition of Blk, JAK3, EGFR, Itk, or Tec activity. BMX-IN-1 was shown to inhibit the proliferation of Tel-BMX-transformed Ba/F3 prostate cancer cells with a GI50 value of 25 nM.{31496} Antiproliferative activity was also observed in RV-1, DU-145, PC-3, and VCAP prostate cancer cell lines (GI50s = 2.54, 4.38, 5.37, and 2.46 µM, respectively).{31496}
Brand:CaymanSKU:-Available on backorder
BMY 7378 is an antagonist of the α2C-adrenoceptor and α1D-adrenoceptor with pKi values of 6.54 and 8.2, respectively, that has been used in functional systems to assess the contribution of these receptors in vascular smooth muscle contraction.{33564,33563} It also acts as a partial agonist at the serotonin 5-HT1A receptor with a pKi value of 8.3.{33564}
Brand:CaymanSKU:21369 -Out of stock
BMY 7378 is an antagonist of the α2C-adrenoceptor and α1D-adrenoceptor with pKi values of 6.54 and 8.2, respectively, that has been used in functional systems to assess the contribution of these receptors in vascular smooth muscle contraction.{33564,33563} It also acts as a partial agonist at the serotonin 5-HT1A receptor with a pKi value of 8.3.{33564}
Brand:CaymanSKU:21369 -Out of stock
BMY 7378 is an antagonist of the α2C-adrenoceptor and α1D-adrenoceptor with pKi values of 6.54 and 8.2, respectively, that has been used in functional systems to assess the contribution of these receptors in vascular smooth muscle contraction.{33564,33563} It also acts as a partial agonist at the serotonin 5-HT1A receptor with a pKi value of 8.3.{33564}
Brand:CaymanSKU:21369 -Out of stock
BMY 7378 is an antagonist of the α2C-adrenoceptor and α1D-adrenoceptor with pKi values of 6.54 and 8.2, respectively, that has been used in functional systems to assess the contribution of these receptors in vascular smooth muscle contraction.{33564,33563} It also acts as a partial agonist at the serotonin 5-HT1A receptor with a pKi value of 8.3.{33564}
Brand:CaymanSKU:21369 -Out of stock
Bobcat 339 is an inhibitor of ten-eleven translocation methylcytosine dioxygenase 1 (TET1) and TET2 (IC50s = 33 and 73 µM, respectively).{61034} It is selective for TET1 and TET2 over DNA methyltransferase 3a (DNMT3a) at 500 µM. Bobcat 339 (10 µM) reduces DNA 5-hydroxymethylcytosine (5-hmC) levels in HT22 hippocampal neurons.
Brand:CaymanSKU:31453 - 1 mgAvailable on backorder
Bobcat 339 is an inhibitor of ten-eleven translocation methylcytosine dioxygenase 1 (TET1) and TET2 (IC50s = 33 and 73 µM, respectively).{61034} It is selective for TET1 and TET2 over DNA methyltransferase 3a (DNMT3a) at 500 µM. Bobcat 339 (10 µM) reduces DNA 5-hydroxymethylcytosine (5-hmC) levels in HT22 hippocampal neurons.
Brand:CaymanSKU:31453 - 10 mgAvailable on backorder
Bobcat 339 is an inhibitor of ten-eleven translocation methylcytosine dioxygenase 1 (TET1) and TET2 (IC50s = 33 and 73 µM, respectively).{61034} It is selective for TET1 and TET2 over DNA methyltransferase 3a (DNMT3a) at 500 µM. Bobcat 339 (10 µM) reduces DNA 5-hydroxymethylcytosine (5-hmC) levels in HT22 hippocampal neurons.
Brand:CaymanSKU:31453 - 25 mgAvailable on backorder
Bobcat 339 is an inhibitor of ten-eleven translocation methylcytosine dioxygenase 1 (TET1) and TET2 (IC50s = 33 and 73 µM, respectively).{61034} It is selective for TET1 and TET2 over DNA methyltransferase 3a (DNMT3a) at 500 µM. Bobcat 339 (10 µM) reduces DNA 5-hydroxymethylcytosine (5-hmC) levels in HT22 hippocampal neurons.
Brand:CaymanSKU:31453 - 5 mgAvailable on backorder
BOC-(1R,3S)-3-Aminocyclopentane carboxylic acid is a synthetic intermediate useful for pharmaceutical synthesis.
Brand:CaymanSKU:11405 - 50 mgAvailable on backorder
BOC-(1S,3R)-3-Aminocyclopentane carboxylic acid is a synthetic intermediate useful for pharmaceutical synthesis.
Brand:CaymanSKU:11406 - 50 mgAvailable on backorder
Boc-Arg(Boc)2-OH is an amino acid building block and derivative of arginine.{46890,46891} It has been used in the synthesis of amino acid prodrug forms of cytotoxic anthraquinones with anticancer activity.{46891}
Brand:CaymanSKU:30522 - 1 gAvailable on backorder
Boc-Arg(Boc)2-OH is an amino acid building block and derivative of arginine.{46890,46891} It has been used in the synthesis of amino acid prodrug forms of cytotoxic anthraquinones with anticancer activity.{46891}
Brand:CaymanSKU:30522 - 500 mgAvailable on backorder
Boc-D-FMK is a cell-permeable, irreversible pan-caspase inhibitor.{26387,26384} Also known as Boc-D(OMe)-FMK, this compound contains a methyl ester group, which facilitates uptake by cells and subsequently is removed by cytoplasmic esterases, leaving the functional inhibitor. Boc-D-FMK blocks apoptosis stimulated by TNF-α in neutrophils (IC50 = 39 µM), by bile duct ligation in hepatocytes, and by TNF-α in renal endothelial cells.{26383,26385,26386} The FMK pharmacophore is known to interact with non-caspase cysteine proteases, presumably explaining why Boc-D-FMK also inhibits cathepsins H and L.{26387}
Brand:CaymanSKU:- Boc-D-FMK is a cell-permeable, irreversible pan-caspase inhibitor.{26387,26384} Also known as Boc-D(OMe)-FMK, this compound contains a methyl ester group, which facilitates uptake by cells and subsequently is removed by cytoplasmic esterases, leaving the functional inhibitor. Boc-D-FMK blocks apoptosis stimulated by TNF-α in neutrophils (IC50 = 39 µM), by bile duct ligation in hepatocytes, and by TNF-α in renal endothelial cells.{26383,26385,26386} The FMK pharmacophore is known to interact with non-caspase cysteine proteases, presumably explaining why Boc-D-FMK also inhibits cathepsins H and L.{26387}
Brand:CaymanSKU:- Boc-D-FMK is a cell-permeable, irreversible pan-caspase inhibitor.{26387,26384} Also known as Boc-D(OMe)-FMK, this compound contains a methyl ester group, which facilitates uptake by cells and subsequently is removed by cytoplasmic esterases, leaving the functional inhibitor. Boc-D-FMK blocks apoptosis stimulated by TNF-α in neutrophils (IC50 = 39 µM), by bile duct ligation in hepatocytes, and by TNF-α in renal endothelial cells.{26383,26385,26386} The FMK pharmacophore is known to interact with non-caspase cysteine proteases, presumably explaining why Boc-D-FMK also inhibits cathepsins H and L.{26387}
Brand:CaymanSKU:-
Boc-D-Leu-OSu is an amino acid-containing building block.{46906,46907} It has been used in the synthesis of peptide gastrin antagonists, as well as analogs of the peptide antibiotic gramicidin S.
Brand:CaymanSKU:30543 - 1 gAvailable on backorder
Boc-D-Leu-OSu is an amino acid-containing building block.{46906,46907} It has been used in the synthesis of peptide gastrin antagonists, as well as analogs of the peptide antibiotic gramicidin S.
Brand:CaymanSKU:30543 - 500 mgAvailable on backorder
Boc-Glu-OBzl is an amino acid building block.{7777,52497} It has been used in the synthesis of peptide-based inhibitors of human caspases and human rhinovirus (HRV) 3C protease that have enzyme inhibitory activity in vitro.
Brand:CaymanSKU:30464 - 1 gAvailable on backorder
Boc-Glu-OBzl is an amino acid building block.{7777,52497} It has been used in the synthesis of peptide-based inhibitors of human caspases and human rhinovirus (HRV) 3C protease that have enzyme inhibitory activity in vitro.
Brand:CaymanSKU:30464 - 5 gAvailable on backorder
Boc-L-Arg-OH is an amino acid building block.{49613,49614,49615} It has been used in the synthesis of antibacterial peptides and as an in vitro model substrate in the study of methylglyoxal peptide crosslinking via the Maillard reaction.
Brand:CaymanSKU:30448 - 1 gAvailable on backorder
Boc-L-Arg-OH is an amino acid building block.{49613,49614,49615} It has been used in the synthesis of antibacterial peptides and as an in vitro model substrate in the study of methylglyoxal peptide crosslinking via the Maillard reaction.
Brand:CaymanSKU:30448 - 5 gAvailable on backorder
Boc-Leu-Leu-OH is a peptide building block.{54085} It has been used in the synthesis of a peptide-based curcumin derivative with anticancer activity in vitro. It has also been used in the synthesis of fluorescent peptides containing naphthalene and protoporphyrin IX.{54086}
Brand:CaymanSKU:30499 - 1 gAvailable on backorder